Humasis Co

Humasis Co Profit per Employee

The Profit per Employee of Humasis Co (205470.KQ) as of Oct 26, 2026 is -64.82 M KRW. In the previous year, Profit per Employee was -126.31 M KRW — a change of -48.69% (higher).

Profit per Employee

-64.82 MKRW

YoY

-48.69%

Last updated:

Profit per Employee of Humasis Co is 2025 -64.82 M KRW. Profit per Employee of Humasis Co was 2024 -126.31 M KRW. It decreases by -48.69% higher compared to the previous year.

The Humasis Co Profit per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Profit per Employee
Date
Profit per Employee
Jan 1, 2018
-3.54 M KRW
Jan 1, 2019
-5.09 M KRW
Jan 1, 2020
87.48 M KRW
Jan 1, 2021
627.40 M KRW
Jan 1, 2022
757.79 M KRW
Jan 1, 2023
-229.98 M KRW
Jan 1, 2024
-126.31 M KRW
Jan 1, 2025
-64.82 M KRW
The Humasis Co Profit per Employee history
YEARProfit per EmployeeYoY
-64.82 MKRW-48.69%
-126.31 MKRW-45.08%
-229.98 MKRW-130.35%
757.79 MKRW+20.78%
627.40 MKRW+617.18%
87.48 MKRW-1,819.35%
-5.09 MKRW+43.79%
-3.54 MKRW-81.92%
-19.57 MKRW-4,365.60%
458,866.14KRW-19.28%
568,454.23KRW+2,198.41%
24,732.45KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Profit per Employee of Humasis Co is -64.82 M KRW in 2025.

Profit per Employee of Humasis Co changed from -126.31 M KRW to -64.82 M KRW, representing a -48.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Humasis Co

All Key Metrics — Humasis Co